Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis

Journal of Burn Care and Research

Volumn 31, Issue 1, 2010, Pages 207-209

  Hallam, M J ^a   Allen, J M ^a   James, S E ^b   Donaldson, P M W ^a   Davies, J G ^c   Hanlon, G W ^b   Dheansa, B S ^a  

^a QUEEN VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRIGHTON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BURN; CASE REPORT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HEART OUTPUT; HUMAN; INFECTION CONTROL; KIDNEY BLOOD FLOW; MALE; SEPSIS;

ACETAMIDES; ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; BURNS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; SEPSIS; THIENAMYCINS;

EID: 75649120690     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e3181c89ee3     Document Type: Article

References (15)

1. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999;44:319-327
2. Zaske DE, Chin T, Kohls P, Solem LD, Strate RG. Initial dosage of gentamicin in patients with burns. J Burn Care Rehabil 1991;12:46-50.
3. Garrelts JC, Jost G, Kowalsky SF, Krol GJ, Lettieri JT. Ciprofloxacin pharmacokinetics in burn patients. Antimicrob Agents Chemother 1996;40:1153-1156
4. Bourget P, Lesne-Hulin A, Le Reveille R, Le Bever H, Carsin H. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 1996;40:139-145
5. Drusano GL, Hutchinson M. The pharmacokinetics of meropenem. Scand J Infect Dis Suppl 1995;96:11-16
6. Gentry-Nielsen MJ, Olsen KM, Preheim LC. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002; 45:1345-1351
7. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
8. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007;44:79-86.
9. Craig WA, Ebert SC, Watanabe Y. Differences in time above the MIC required for efficacy of beta-lactams in animal infection models. In: 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington DC; 1993, abstract 86.
10. Walker R, Andes D, Conklin R, Evert S, Craig W. Pharmacodynamic activities of meropenem in an animal infection model. In: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology: Washington DC; 1994, abstract A91.
11. Scaglione F, Paraboni L. Pharmacokinetics/pharmacodynamics of antibacterials in the intensive care unit: setting appropriate dosing regimens. Int J Antimicrob Agents 2008; 32:294-301.
12. A Guide to Sensitivity Testing. Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 1991;27(suppl D):1-50.
13. Andes D, Van Ogtrop ML, Craig WA. Pharacodynamics Activity of a New Oxazolidinone, Linezolid, in an Animal Infection Model (Abstract 08.16). International Conference on the Macrolides, Streptogramins, Ketolides and Oxazolidinones; Seville, 2000.
14. Gentry-Nielsen MJ, Olsen KM, Preheim LC. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002; 46:1345-1351
15. Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/ pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008;31:122-129